




Searching News Database: Bayer Pharmaceuticals
HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 3 Nov 2017
Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations
Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations
HSMN NewsFeed - 14 May 2012
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
HSMN NewsFeed - 12 Feb 2008
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
HSMN NewsFeed - 26 Mar 2007
Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
HSMN NewsFeed - 25 Jan 2007
Bayer Discontinues Trasylol(R) Clinical Trial Program in Non-CABG Indications
Bayer Discontinues Trasylol(R) Clinical Trial Program in Non-CABG Indications
HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
HSMN NewsFeed - 28 Nov 2006
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Additional items found! 77

Members Archive contains
77 additional stories matching:
Bayer Pharmaceuticals
(Password required)
Bayer Pharmaceuticals
(Password required)